Samuel Denmeade

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug
    W Nathaniel Brennen
    Department of Pharmacology and Molecular Sciences, The Johns Hopkins University, Baltimore, MD, USA
    J Natl Cancer Inst 104:1320-34. 2012
  2. pmc Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy
    Samuel R Denmeade
    The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Sci Transl Med 4:140ra86. 2012
  3. pmc Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy
    W Nathaniel Brennen
    Department of Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, Maryland, USA
    Mol Cancer Ther 11:257-66. 2012
  4. doi request reprint Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer
    Samuel R Denmeade
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Prostate 70:1600-7. 2010
  5. ncbi request reprint Development of prostate cancer treatment: the good news
    Samuel R Denmeade
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Prostate 58:211-24. 2004
  6. ncbi request reprint The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer
    Samuel R Denmeade
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Biol Ther 4:14-22. 2005
  7. ncbi request reprint Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer
    Samuel R Denmeade
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    J Natl Cancer Inst 95:990-1000. 2003
  8. ncbi request reprint Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo
    Samuel R Denmeade
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Prostate 56:45-53. 2003
  9. ncbi request reprint Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models
    Samuel R Denmeade
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Prostate 54:249-57. 2003
  10. ncbi request reprint A history of prostate cancer treatment
    Samuel R Denmeade
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Nat Rev Cancer 2:389-96. 2002

Collaborators

Detail Information

Publications43

  1. pmc Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug
    W Nathaniel Brennen
    Department of Pharmacology and Molecular Sciences, The Johns Hopkins University, Baltimore, MD, USA
    J Natl Cancer Inst 104:1320-34. 2012
    ..FAP is therefore a provocative target for the activation of prodrugs consisting of a FAP-specific peptide coupled to a potent cytotoxic analog of TG...
  2. pmc Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy
    Samuel R Denmeade
    The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Sci Transl Med 4:140ra86. 2012
    ..On the basis of these data, a phase 1 dose-escalation clinical trial has been initiated with G202 in patients with advanced cancer...
  3. pmc Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy
    W Nathaniel Brennen
    Department of Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, Maryland, USA
    Mol Cancer Ther 11:257-66. 2012
    ....
  4. doi request reprint Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer
    Samuel R Denmeade
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Prostate 70:1600-7. 2010
    ..The goal is to determine if a clinical response can be achieved through this non-adaptive rapid cycling approach in men with CRPC...
  5. ncbi request reprint Development of prostate cancer treatment: the good news
    Samuel R Denmeade
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Prostate 58:211-24. 2004
    ..Continued allocation of appropriate human and material resources should yield new, more effective therapies for prostate cancer that will further impact patient quality of life and survival in the 21st century...
  6. ncbi request reprint The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer
    Samuel R Denmeade
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Biol Ther 4:14-22. 2005
    ..These prodrugs are currently undergoing preclinical evaluation as potential targeted therapy for prostate cancer...
  7. ncbi request reprint Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer
    Samuel R Denmeade
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    J Natl Cancer Inst 95:990-1000. 2003
    ..e., G0-arrested) cells. However, thapsigargin's mechanism of action indicates that it is unlikely to be selective for cancer cells or prostate cells...
  8. ncbi request reprint Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo
    Samuel R Denmeade
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Prostate 56:45-53. 2003
    ..Recent data also suggest that the PSA protein itself, independent of enzymatic activity, may also function as an endothelial cell-specific inhibitor of angiogenesis...
  9. ncbi request reprint Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models
    Samuel R Denmeade
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Prostate 54:249-57. 2003
    ..regulation of expression of prostate differentiation specific markers PSA, hK2, and PSMA...
  10. ncbi request reprint A history of prostate cancer treatment
    Samuel R Denmeade
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Nat Rev Cancer 2:389-96. 2002
    ..What were the first ways in which prostate cancer was treated, and how did these evolve into the variety of therapeutic strategies from which patients have to choose today?..
  11. pmc Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia
    Samuel R Denmeade
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Eur Urol 59:747-54. 2011
    ....
  12. pmc The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation
    Daniel Keizman
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Prostate 71:1608-15. 2011
    ..We sought to determine the change of PSA doubling time (PSADT) and its association with disease progression during intermittent androgen deprivation (IAD) therapy for prostate cancer...
  13. pmc Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer
    Jianqing Lin
    Prostate Cancer Program, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Urol Oncol 29:670-5. 2011
    ....
  14. pmc Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study
    Daniel Keizman
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Clin Cancer Res 16:5269-76. 2010
    ..To evaluate the safety and activity of 6 months of treatment with lenalidomide at 5 or 25 mg/d in nonmetastatic biochemically relapsed prostate cancer...
  15. pmc Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin
    Aaron M LeBeau
    Department of Pharmacology and Molecular Sciences, The Johns Hopkins University, Baltimore Maryland 21231, USA
    Mol Cancer Ther 8:1378-86. 2009
    ..Intratumoral injection of an FAP-activated protoxin produced significant lysis and growth inhibition of human breast and prostate cancer xenografts with minimal toxicity to the host animal...
  16. ncbi request reprint Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity
    Ravibhushan Singh
    Cancer Research Institute, Scott and White Memorial Hospital, 5701 South Airport Road, Temple, TX 76502, USA
    Anticancer Drugs 18:809-16. 2007
    ..Our results suggest that recombinant modified proaerolysin is a potent prostate-specific antigen-sensitive protoxin that deserves further development for regional therapy of benign and malignant prostate growths...
  17. ncbi request reprint Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint
    Connie Collins
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Biol Ther 6:1360-7. 2007
    ..CEP-701 binds to serum proteins and a preprostatectomy study was performed to assess prostate tissue penetration and clinical response to CEP-701...
  18. ncbi request reprint A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer
    Sachin S Chandran
    Department of Chemical and Biomolecular Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Mol Cancer Ther 6:2928-37. 2007
    ..Analysis of tumor tissue from mice treated with a single or multiple dose of the HPMA-JHPD copolymer showed release and accumulation of the L12ADT toxin within the tumor tissue...
  19. pmc Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer
    Dana Rathkopf
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 26:2959-65. 2008
    ..We evaluated rapid androgen cycling in combination with docetaxel for men with progressive noncastrate prostate cancers...
  20. pmc Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen
    Aaron M LeBeau
    Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Chem Biol 15:665-74. 2008
    ..The inhibitor had a 60-fold higher K(i) for chymotrypsin. A validated model of PSA's catalytic site confirmed the critical interactions between the inhibitor and residues within the PSA enzyme...
  21. ncbi request reprint CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth
    Christopher J Strock
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 63:5559-63. 2003
    ..CEP-751 and its prodrug, CEP-2563, also inhibited tumor growth in MTC cell xenografts. These results show that inhibiting RET can block the growth of MTC cells and may have a therapeutic benefit in MTC...
  22. ncbi request reprint Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy
    Gopal K Bajaj
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Urology 69:526-31. 2007
    ..This Phase II study was undertaken to determine the safety and efficacy of imatinib mesylate in men with biochemical relapse of nonmetastatic, androgen-sensitive prostate cancer after local therapy...
  23. ncbi request reprint A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease
    Simon A Williams
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Natl Cancer Inst 99:376-85. 2007
    ..Prostate-specific antigen (PSA) is a serine protease that is secreted at high levels by the normal and diseased prostate. Therapies that are activated by PSA may prove effective in treating prostatic malignancies...
  24. ncbi request reprint Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer?
    Simon A Williams
    The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Prostate 67:312-29. 2007
    ....
  25. ncbi request reprint Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug
    Samuel Janssen
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Prostate 66:358-68. 2006
    ....
  26. ncbi request reprint Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase
    Pratap Singh
    Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland 21218, USA
    J Med Chem 48:3005-14. 2005
    ....
  27. ncbi request reprint Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human
    Saurabh Aggarwal
    Department of Chemical and Biomolecular Engineering, The Johns Hopkins University Whiting School of Engineering, Baltimore, Maryland 21231, USA
    Prostate 66:903-10. 2006
    ..Intraprostatic PSMA targeted prodrugs/protoxins are under development in our laboratory. Future toxicologic studies of these therapies require identification of animal models that express PSMA within the prostate...
  28. ncbi request reprint Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers
    Yi Xu
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Clin Cancer Res 12:4072-9. 2006
    ..Therefore, the levels of expression SRD5A1 and SRD5A2 and the antiprostatic cancer growth response to finasteride, a selective SRD5A2 inhibitor, versus the dual SRD5A1 and SRD5A2 inhibitor, dutasteride, were compared...
  29. ncbi request reprint Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts
    Jacek Pinski
    Johns Hopkins Oncology Center, Baltimore, Maryland 21231 1000, USA
    Cancer Res 62:986-9. 2002
    ..These combined results demonstrate that proliferating osteoblasts acquire a sensitivity to trk inhibition- induced apoptosis not shared with normally quiescent osteoblasts...
  30. ncbi request reprint Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma
    Victoria J Sinibaldi
    Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Am J Clin Oncol 29:395-8. 2006
    ....
  31. ncbi request reprint Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer
    Samuel Janssen
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD 21231, USA
    Mol Cancer Ther 3:1439-50. 2004
    ....
  32. ncbi request reprint A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity
    Saurabh Aggarwal
    The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 66:9171-7. 2006
    ..These dimeric peptides, therefore, represent putative PSMA-selective targeting agents that are currently being evaluated for selective binding in vivo...
  33. ncbi request reprint Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA)
    Annastasiah Mhaka
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Cancer Biol Ther 3:551-8. 2004
    ..These studies have identified PSMA selective, plasma stable peptide substrates that can be incorporated into prodrugs targeted for activation by PSMA within prostate cancer sites...
  34. ncbi request reprint Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation
    Rena G Lapidus
    Guilford Pharmaceuticals, Inc, Baltimore, Maryland, USA
    Prostate 58:291-8. 2004
    ..Local delivery of a controlled-release paclitaxel product may allow for increase local concentrations of paclitaxel at the tumor site and, in conjunction with radiation, may enhance cell kill by its radiosensitization mechanism...
  35. ncbi request reprint Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer
    Christopher J Strock
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    J Clin Endocrinol Metab 91:79-84. 2006
    ..Medullary thyroid cancer (MTC) is a cancer of the parafollicular C cells that commonly presents with an inherited or acquired RET gene mutation. There is currently no effective systemic treatment for MTC...
  36. ncbi request reprint A combinatorial approach to the selective capture of circulating malignant epithelial cells by peptide ligands
    Saurabh Aggarwal
    The Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
    Biomaterials 26:6077-86. 2005
    ..When immobilized on appropriate surfaces, these peptides could be used in both in vivo and ex vivo cell separation devices to efficiently and selectively capture metastatic epithelial cancer cells from flowing blood...
  37. pmc Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA)
    Sachin S Chandran
    The Department of Chemical and Biomolecular Engineering, The Johns Hopkins University Whiting School of Engineering, Baltimore, Maryland 21231, USA
    Cancer Biol Ther 7:974-82. 2008
    ..Ongoing in vivo studies address the localization, activity and toxicity of these targeted nanoparticles against PSMA-producing human prostate tumor xenografts...
  38. ncbi request reprint Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells
    Helmer Søhoel
    Department of Medicinal Chemistry, The Danish University of Pharmaceutical Sciences, Universitetsparken 2, DK 2100 Copenhagen, Denmark
    Bioorg Med Chem 14:2810-5. 2006
    ..Only the 12-Boc-aminododecaonoyl derivative, however, was found to be apoptotic...
  39. ncbi request reprint Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites
    Saurabh Aggarwal
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University, Baltimore, Maryland 21231, USA
    Biochemistry 47:1076-86. 2008
    ..On the basis of these results, the FAP consensus sequences are currently being evaluated as FAP-selective peptide carriers for incorporation into FAP-activated prodrugs...
  40. ncbi request reprint Mechanistic insights into the inhibition of prostate specific antigen by beta-lactam class compounds
    Pratap Singh
    Department of Chemical and Biomolecular Engineering, Whiting School of Engineering, The Johns Hopkins University, Baltimore, Maryland 21218, USA
    Proteins 70:1416-28. 2008
    ..The close agreement of our docking results with the experimental data validates the mechanistic insights revealed through the docking studies and paves the way for the design and development of potent and specific inhibitors of PSA...
  41. ncbi request reprint Cytotoxic phenylpropanoids and an additional thapsigargin analogue isolated from Thapsia garganica
    Huizhen Liu
    Department of Medicinal Chemistry, The Danish University of Pharmaceutical Sciences, Universitetsparken 2, DK 2100 Copenhagen Ø, Denmark
    Phytochemistry 67:2651-8. 2006
    ..A spectroscopic method for elucidating the relative stereochemistry at the two pairs of stereogenic centers in the phenylpropanoids has been developed. The phenylpropanoids were found to be potent cytotoxins...
  42. ncbi request reprint Modulating paclitaxel bioavailability for targeting prostate cancer
    Srinivas K Kumar
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA
    Bioorg Med Chem 15:4973-84. 2007
    ....
  43. doi request reprint Left posterior fascicular block due to high-dose interleukin-2
    Anand Singla
    Department of Internal Medicine, Johns Hopkins University, Sinai Hospital of Baltimore, Baltimore, MD, USA
    Ann Pharmacother 42:1340-3. 2008
    ..To report a case of reversible left posterior fascicular block (LPFB) associated with high-dose interleukin-2 (IL-2) therapy...

Research Grants4

  1. Fibroblast Activation Protein-alpha Activated Anti-Stromal Prodrug Therpay for Ca
    Samuel Denmeade; Fiscal Year: 2007
    ..e. "stroma") within cancers rather than the cancer cells themselves can be effective therapy. The FAP- activated prodrug, therefore, could represent a new targeted therapy for a variety of human cancers. ..
  2. Fibroblast Activation Protein-alpha Activated Anti-Stromal Prodrug Therpay for Ca
    Samuel Denmeade; Fiscal Year: 2009
    ..e. "stroma") within cancers rather than the cancer cells themselves can be effective therapy. The FAP- activated prodrug, therefore, could represent a new targeted therapy for a variety of human cancers. ..
  3. Fibroblast Activation Protein-alpha Activated Anti-Stromal Prodrug Therpay for Ca
    Samuel R Denmeade; Fiscal Year: 2010
    ..e. "stroma") within cancers rather than the cancer cells themselves can be effective therapy. The FAP- activated prodrug, therefore, could represent a new targeted therapy for a variety of human cancers. ..